Skip to main content
Contact Us
Subscribe
E-Edition
69°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Cybin Inc
(NY:
CYBN
)
0.3616
-0.0084 (-2.27%)
Streaming Delayed Price
Updated: 10:55 AM EDT, May 10, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Cybin Inc
< Previous
1
2
...
30
31
32
33
34
35
36
37
Next >
Cybin Witnessing Advancement in R&D Pipeline
December 29, 2021
Cybin (NYSE: CYBN), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, recently released its financial and operating...
Via
Benzinga
Cybin (NYSE American: CYBN) (NEO: CYBN) Witnessing Advancement in R&D Pipeline
December 29, 2021
Via
Investor Brand Network
Exposures
Product Safety
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Witnessing Swift Advancement in R&D Pipeline, Overall Business
December 28, 2021
Via
Investor Brand Network
Exposures
Product Safety
Steep Decline In Cannabis & Psychedelic Compounds-Based Drug Stocks Continues: DOWN -16.6% MTD
December 24, 2021
All 12 constituents in the Marijuana & Psychedelic Compounds-Based Drug Stocks Index continue to decline. How do their performances compare month-to-date and YTD?
Via
Talk Markets
Cybin (NYSE American: CYBN) (NEO: CYBN) Issues 2021 Year-End Summary
December 22, 2021
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Issues 2021 Year-End Summary
December 22, 2021
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Cybin Provides 2021 Year End Summary
December 22, 2021
From
Cybin Inc.
Via
Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Participation in Upcoming January Events
December 21, 2021
Via
Investor Brand Network
Cybin to Participate in the 11th Annual LifeSci Partners Corporate Access Event and H.C. Wainwright Bioconnect Conference
December 21, 2021
From
Cybin Inc.
Via
Business Wire
Marijuana & Psychedelic Compounds-Based Drug Stocks Now Down -16% YTD
December 17, 2021
A look at which index has done the best so far in December: the Marijuana Drug Stocks Index or the Psychedelic Compounds-Based Drug Stocks Index.
Via
Talk Markets
Why Some Psychedelic Assisted Therapy Clinics Are Turning To Artificial Intelligence for Digital Mental Therapies
December 16, 2021
Palm Beach, FL –December 16, 2021 – FinancialNewsMedia.com News Commentary – Drugs like ketamine and psilocybin — the active ingredient in magic mushrooms — are showing real promise in addressing...
Via
FinancialNewsMedia
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Cybin Receives Notice of Allowance from U.S. Patent Office
December 15, 2021
Cybin (NYSE: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, has been awarded a Notice of Allowance from the U.S. Patent and Trademark Office (...
Via
Benzinga
Cybin (NEO: CYBN) (NYSE American: CYBN) Receives Notice of Allowance from U.S. Patent Office
December 15, 2021
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Receives Notice of Allowance from U.S. Patent Office for Exclusive Anxiety Disorder Treatment
December 15, 2021
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Cybin Awarded Notice of Allowance from U.S. Patent and Trademark Office for CYB004 (Deuterated Psychedelic Tryptamine) for the Treatment of Anxiety Disorders
December 15, 2021
From
Cybin Inc.
Via
Business Wire
Cybin Developing Safer, More Effective Psilocybin Therapies
December 14, 2021
Cybin (NYSE: CYBN), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, recently announced positive results from a...
Via
Benzinga
Cybin (NYSE American: CYBN) (NEO: CYBN) Developing Safer, More Effective Psilocybin Therapies
December 14, 2021
Via
Investor Brand Network
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Developing Safer, More Effective Psilocybin Therapies for Patients
December 13, 2021
Via
Investor Brand Network
Cybin to Fund, Support Psychedelic Clinic at Manhattan Hospital
December 10, 2021
Company receives grant to fund clinic for marginalized, underserved NYC communities New clini...
Via
Benzinga
Cybin (NEO: CYBN) (NYSE American: CYBN) to Fund, Support Psychedelic Clinic at Manhattan Hospital
December 10, 2021
Via
Investor Brand Network
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) to Fund, Support First-Ever Psychedelic Treatment Clinic at Manhattan Hospital
December 09, 2021
Via
Investor Brand Network
Psilera's DMT-Derived Drug Sees Positive Results in Pre-Clinical Study
December 09, 2021
Psilera is a Florida-based biotechnology company focused on developing drugs to treat mental disorders using non-hallucinogenic derivatives from psychedelic compounds. The...
Via
Benzinga
Topics
Derivatives
Exposures
Derivatives
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Moving Rapidly to Progress CYB003 Toward Clinical Development
December 08, 2021
Via
Investor Brand Network
Cybin Confirms Scientific Advice Meeting with UK Medical and Healthcare Products Regulatory Agency for Lead Candidate CYB003 for the Treatment of Major Depressive Disorder and Alcohol Use Disorder
December 08, 2021
From
Cybin Inc.
Via
Business Wire
Cybin Touts Highlights of 'Transformative' Second-Quarter Performance
December 02, 2021
The report notes significant and swift advancements in the company R&D pipeline and overall business Preliminary data indicates CYB003 may provide significant treatment...
Via
Benzinga
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Touts Highlights of ‘Transformative’ Second-Quarter Performance
December 02, 2021
Via
Investor Brand Network
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Participation in Future of Healthcare Conference
December 02, 2021
Via
Investor Brand Network
Cybin to Present at the Stifel GMP 2nd Annual Future of Healthcare Conference on December 8, 2021
December 01, 2021
From
Cybin Inc.
Via
Business Wire
Cybin Announces FDA Approvals, Participation in Conference
December 01, 2021
Cybin (NYSE:
Via
Benzinga
Exposures
Product Safety
Psilocybin Trials For COVID-Related Distress Of Healthcare Professionals Could Validate New Psychotherapy Model
November 30, 2021
Cybin (NYSE:CYBN), a biotech company focused on progressing ...
Via
Benzinga
< Previous
1
2
...
30
31
32
33
34
35
36
37
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.